GlobeNewswire by notified

Curium Announces First Commercial Doses in Germany of PYLCLARI® – An Innovative 18F-PSMA PET Tracer Indicated in Patients With Prostate Cancer

Share

PARIS, May 06, 2024 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced that today in Munich and Nurnberg, Germany the first commercial doses of PYLCLARI® have been delivered. PYLCLARI® (INN: Piflufolastat (18F) also known as (18F)-DCFPyL), is indicated for the detection of prostate-specific membrane antigen (PSMA) positive lesions with positron emission tomography (PET) in patients with prostate cancer in the following clinical settings:

  • Primary staging of patients with high-risk prostate cancer prior to initial curative therapy
  • To localize recurrence of prostate cancer in patients with a suspected recurrence based on increasing serum prostate-specific antigen (PSA) levels after primary treatment with curative intent

Benoit Woessmer, PET Europe CEO at Curium commented, “We are pleased with the growing availability of PYLCLARI® to more nuclear medicine physicians and their patients across Europe. With today’s announcement, we are extremely proud to be improving the choice of diagnostic modalities available to our customers in Germany – ultimately for the benefit of patients with prostate cancer.”

In Germany, prostate cancer is the most common cancer among men with around 63,400 new cases diagnosed nationwide every year. Today’s announcement is part of the continued roll-out of PYLCLARI® across the European Union, which is now available for patients with prostate cancer in Greece, Italy, and the Netherlands.

For more information about PYLCLARI®: www.pylclari.com

In the U.S., Lantheus received approval for PYLARIFY® (Piflufolastat (18F) Injection) from the Food and Drug Administration (FDA) in May 2021. It is the #1 utilized PSMA PET agent in the U.S. market. The European rights were licensed by Curium from Progenics, a Lantheus company, in 2018. 

About Curium

Curium is a world leader in nuclear medicine. We develop, manufacture, and distribute world-class radiopharmaceutical products to help patients around the globe. Our proven heritage combined with a pioneering approach are the hallmarks to deliver innovation, excellence, and unparalleled service.

With manufacturing facilities across Europe and the United States, Curium delivers SPECT, PET and therapeutic radiopharmaceutical solutions for life-threatening diseases to over 14 million patients annually. The name ‘Curium’ honors the legacy of pioneering radioactive materials researchers Marie and Pierre Curie, after whom the radioactive element curium was named and emphasizes our focus on nuclear medicine. To learn more, visit www.curiumpharma.com

For more information:
Ross Bethell, VP, Head of Global Communications
Curium
communications@curiumpharma.com

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Ice Fish Farm – Proposed change of company name30.5.2024 11:45:07 CEST | Press release

Reykjavík, 30 May 2024 - The board of directors of Ice Fish Farm AS (the "Company") will propose that the general meeting resolves to change the company name to Kaldvik AS at the Company's annual general meeting on 20 June 2024. If approved, the Company will be trading under a new name and a new ticker immediately following the general meeting. The Company is trading its shares under the ticker "KLDVK" on Nasdaq First North Iceland already prior to the general meeting. Contacts: Róbert Róbertsson, CFO of ICE FISH FARM AS: +354 8430086 About Ice Fish Farm: Ice Fish Farm is listed on Euronext Growth Oslo. The company is the 100% owner of Fiskeldi Austfjarða ehf., the leading farming company in Iceland with its head office in Eskifjörður. The Company is fully integrated with control over all parts of the value chain. See https://www.icefishfarm.is for more information about the Company. This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Secur

Rentetillæg fastsat på SDRO udstedt af Realkredit Danmark A/S30.5.2024 11:42:59 CEST | pressemeddelelse

Realkredit Danmark har fastsat tillæg på obligationer i serie 11F, 12E og 12F Realkredit Danmark offentliggør hermed tillæg til referencerenten på obligationerne bag FlexKort®, RD Cibor6® Green og RD Cibor6® som udstedes i forbindelse med refinansieringen pr. 1. juli 2024. Opdaterede Endelige vilkår offentliggøres hermed. Eventuelle spørgsmål kan rettes til Hella Gebhardt Rønnebæk, tlf. 45 13 20 68. Vedhæftede filer NewFinalTerms11FMAJ2024DKiiNewFinalTerms12FMAJ2024DKiiNewFinalTerms12EMAJ2024DKii

Publication of a Company Description30.5.2024 11:38:20 CEST | Press release

Kaldvík (Ice Fish Farm) has published a Company Description in relation to the admission to trading of the Company's Affiliated Shares on Nasdaq First North Growth Market Iceland. The Company Description, dated 24 May 2024 is attached. Nasdaq First North Growth Market Disclaimer Nasdaq First North Growth Market is a registered SME growth market, in accordance with the Directive on Markets in Financial Instruments (EU 2014/65) as implemented in the national legislation of Denmark, Finland, Iceland and Sweden, operated by an exchange within the Nasdaq group. Issuers on Nasdaq First North Growth Market are not subject to all the same rules as issuers on a regulated main market, as defined in EU legislation (as implemented in national law). Instead, they are subject to a less extensive set of rules and regulations adjusted to small growth companies. The risk in investing in an issuer on Nasdaq First North Growth Market may therefore be higher than investing in an issuer on the main market.

Selskabsmeddelelse nr. 6, 2023/2430.5.2024 11:15:00 CEST | pressemeddelelse

Investeringsselskabet Luxor A/S’ bestyrelse har dags dato godkendt halvårsrapport pr. 31. marts 2024. 2. kvartal 2023/24: Basisindtjeningen er kr. 10,0 mio. (kr. 12,2 mio.). Resultat før skat er kr. 14,1 mio. (kr. 12,1 mio.). Kvartalets resultat før skat er kr. 4,1 mio. højere end basisindtjeningen, hvilket skyldes:kr. 2,5 mio. fra dagsværdiregulering af finansielle aktiver. kr. 1,6 mio. fra dagsværdiregulering af renteswaps og gæld til realkreditinstitutter. Halvåret 2023/24: Basisindtjeningen er kr. 21,9 mio. (kr. 21,7 mio.). Koncernens resultat før skat er kr. 12,9 mio. (kr. 20,3 mio.). Halvårets resultat er kr. 9,0 mio. lavere end basisindtjeningen, hvilket skyldes: kr. 5,3 mio. fra dagsværdiregulering af finansielle aktiver. kr. -14,3 mio. fra dagsværdiregulering af renteswaps og gæld til realkreditinstitutter samt omkostninger til optagelse af realkreditlån. Forventet basisindtjening 2023/24: For regnskabsåret 2023/24 forventes på indeværende tidspunkt en basisindtjening i niveau

Prosafe SE: Prosafe issued Conditional Letter of Intent for Safe Boreas30.5.2024 11:08:50 CEST | Press release

Oslo, 30 May 2024 Prosafe has been issued a Conditional Letter of Intent (CLoI) for the Safe Boreas to provide gangway connected operations to support a project off the coast of Western Australia. The CLoI is conditional upon execution of a final contract. The firm duration of the contract linked to the CLoI is 15 months with up to six months of options. The Safe Boreas will mobilise from the North Sea within Q2 2025. Safe Boreas will undergo its five-yearly special periodic survey and other maintenance works prior to commencement of the contract. The value of the contract linked to the CLoI is approximately USD 75 million to USD 100 million depending on options. The Safe Boreas is one of the world’s most advanced and versatile semi-submersible DP-3 accommodation vessels and complies with stringent rules in Australia, Norway and UK. Single person cabins, extensive recreation facilities, combined with a large deck area, cranes and passive motion compensated gangway will ensure the highe

HiddenA line styled icon from Orion Icon Library.Eye